Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI intervention study

被引:36
作者
Roux, Perrine [1 ,2 ,3 ]
Le Gall, Jean-Marie [4 ]
Debrus, Marie [5 ]
Protopopescu, Camelia [1 ,2 ,3 ]
Ndiaye, Khadim [1 ,2 ,3 ]
Demoulin, Baptiste [1 ,2 ,3 ]
Lions, Caroline [1 ,2 ,3 ]
Haas, Aurelie [4 ]
Mora, Marion [1 ,2 ,3 ]
Spire, Bruno [1 ,2 ,3 ,4 ]
Suzan-Monti, Marie [1 ,2 ,3 ,4 ]
Carrieri, Maria Patrizia [1 ,2 ,3 ]
机构
[1] INSERM U912 SESSTIM, Marseille, France
[2] Aix Marseille Univ, Marseille, France
[3] ORS PACAObserv Reg Sante Provence Alpes Cote Azur, Grenoble, France
[4] AIDES, Marseille, France
[5] Med Moncle, Paris, France
关键词
Education; HCV; HIV; injecting drug user; intervention; local complications; GENDER-DIFFERENCES; USERS; BEHAVIORS; TRANSMISSION; VANCOUVER; PROGRAMS; FACILITY; COHORT; COMPLICATIONS; EPIDEMIOLOGY;
D O I
10.1111/add.13089
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
AimsTo study the effectiveness of an educational intervention on risks associated with drug injection, comparing primary [unsafe HIV-hepatitis C virus (HCV) practices] and secondary (local complications at injecting site) end-points in harm reduction (HR) programmes offering this intervention versus HR programmes not offering it. DesignThis non-random clustered intervention study was conducted in nine intervention groups (programmes offering the intervention) and eight control groups (programmes not offering it). Each participant was followed-up through a telephone interview at enrolment and at 6 and 12 months. SettingThe study took place in 17 cities throughout France. ParticipantsOf the 271 participants, 144 were enrolled into the intervention group and 127 in the control group. Of the latter, 113 received at least one educational session. InterventionA series of participant-centred face-to-face educational sessions. Each session included direct observation by trained non-governmental organization (NGO) staff or volunteers of participants' self-injecting the psychoactive product they used habitually; analysis by the trained NGO staff or volunteers of the participant's injecting practices, identification of injection-related risks and explanation of safer injecting practices; and an educational exchange on the individual participant's injection practices and the questions he or she asked. MeasurementsPrimary and secondary outcomes were at least one unsafe HIV-HCV practice' and at least one injection-related complication (derived from a checklist). FindingsThe proportion of participants with at least one unsafe HIV-HCV practice in the intervention group decreased significantly, from 44% at M0 to 25% at M6, as well as complications at the injection site (from 66 to 39% at M12), while in the control group it remained mainly stable. Multivariate probit analyses showed that the intervention group experienced a significant reduction in unsafe HIV-HCV practices at M6 [coefficient, 95% confidence interval (CI)=-0.73 (-1.47 to 0.01)] and in injection-related complications at M12 [coefficient, 95% CI=-1.01 (-1.77 to -0.24)], compared with the control group. ConclusionsAn inexpensive and easily implemented educational intervention on risks associated with drug injection reduces significantly unsafe HIV-HCV transmission practices and injection-related complications.
引用
收藏
页码:94 / 106
页数:13
相关论文
共 46 条
  • [31] Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews
    Nelson, Paul K.
    Mathers, Bradley M.
    Cowie, Benjamin
    Hagan, Holly
    Des Jarlais, Don
    Horyniak, Danielle
    Degenhardt, Louisa
    [J]. LANCET, 2011, 378 (9791) : 571 - 583
  • [32] Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data
    Palmateer, N.
    Hutchinson, S.
    McAllister, G.
    Munro, A.
    Cameron, S.
    Goldberg, D.
    Taylor, A.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2014, 21 (01) : 25 - 32
  • [33] Injection drug use - An understudied cause of venous disease
    Pieper, Barbara
    Kirsner, Robert S.
    Templin, Thomas N.
    Birk, Thomas J.
    [J]. ARCHIVES OF DERMATOLOGY, 2007, 143 (10) : 1305 - 1309
  • [34] Harmful Microinjecting Practices Among a Cohort of Injection Drug Users in Vancouver Canada
    Rachlis, Beth
    Lloyd-Smith, Elisa
    Small, Will
    Tobin, Diane
    Stone, Dave
    Li, Kathy
    Wood, Evan
    Kerr, Thomas
    [J]. SUBSTANCE USE & MISUSE, 2010, 45 (09) : 1351 - 1366
  • [35] Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users
    Roux, Perrine
    Carrieri, M. Patrizia
    Keijzer, Lenneke
    Dasgupta, Nabarun
    [J]. DRUG AND ALCOHOL REVIEW, 2011, 30 (03) : 287 - 290
  • [36] Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being
    Ryan, RM
    Deci, EL
    [J]. AMERICAN PSYCHOLOGIST, 2000, 55 (01) : 68 - 78
  • [37] Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review
    Sacks-Davis, Rachel
    Horyniak, Danielle
    Grebely, Jason
    Hellard, Margaret
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2012, 23 (03) : 176 - 184
  • [38] Comparing longitudinal binary outcomes in an observational oral health study
    Shelton, BJ
    Gilbert, GH
    Lu, ZM
    Bradshaw, P
    Chavers, LS
    Howard, G
    [J]. STATISTICS IN MEDICINE, 2003, 22 (12) : 2057 - 2070
  • [39] A continuing concern: HIV and hepatitis testing and prevalence among drug users in substitution programmes in Zurich, Switzerland
    Somaini, B
    Wang, J
    Perozo, M
    Kuhn, F
    Meili, D
    Grob, P
    Flepp, M
    [J]. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 2000, 12 (04): : 449 - 460
  • [40] Age and sharing of needle injection equipment in a cohort of Massachusetts injection drug users: An observational study
    Tassiopoulos K.
    Bernstein J.
    Bernstein E.
    [J]. Addiction Science & Clinical Practice, 8 (1)